

Curriculum Vitae

Ilya Kister, MD, FAAN

240 East 38th Street, 18th floor
New York, NY 10016
w. (212) 598-6305
c. (908) 227-2329
ilya.kister@nyumc.org

Current Appointments

2016 - present Associate Professor (Clinical), NYU School of Medicine
2011 - present Director, Neuroimmunology Fellowship, NYU School of Medicine
2016 - present Director, Neuromyelitis Optica Program, NYU School of Medicine
2007 - present Attending, Department of Neurology, NYU Langone Medical Center
2010 - present Attending, Department of Medicine, Barnabas-RWJ, Livingston, NJ

Education and Training

1997 B.S. (Cum Laude), Applied Physics, Rutgers University, New Brunswick, NJ
1998 - 2002 MD, Mount Sinai School of Medicine, New York, NY
2002 - 2003 Internship, Internal Medicine, Maimonides Medical Center, New York, NY
2003 - 2006 Residency, Adult Neurology, Albert Einstein College of Medicine, New York, NY
2006 - 2007 Fellowship in Multiple Sclerosis, NYU MS Care Center, NYU Langone Health, New York, NY

Professional Experience

2007 - 2008 Instructor, NYU School of Medicine
2008 - 2016 Assistant Professor (Clinical), NYU School of Medicine
2007 - 2011 Consulting Physician, Neuro-rehabilitation Inpatient Unit, NYU Langone Medical Center
2007 - present Attending, Department of Neurology, NYU Langone Medical Center
2010 - present Attending, Department of Medicine Barnabas-RWJ, Livingston, NJ
2011 - present Director, Neuroimmunology Fellowship NYU School of Medicine
2016 - present Director, Neuromyelitis Optica Program NYU School of Medicine
2016 - present Associate Professor (Clinical), NYU School of Medicine

Peer Reviewed Original Scientific Publications

1. Mirochnitchenko O, Prokopenko O, Palnitkar U, **Kister I**, Powell W, Inouye M. Endotoxemia in Transgenic Mice Overexpressing Human Glutathione Peroxidases. *Circulation Research* 2000; 87:289.
2. **Kister I**, Gulati S, Boz C, Bergamaschi R, Piccolo G, Oger J, Swerdlow M. Emergence of neuromyelitis optica in four patients with myasthenia gravis who underwent thymectomy. *Arch Neurol* 2006; 63(6):851-6.
3. **Kister I**, Inglese M, Laxer RM, Herbert J. Neurologic manifestations of localized scleroderma: A case report and literature review. *Neurology* 2008; 71:1538-45.
4. Graber JJ, **Kister I**, Geyer H, Khaund M, Herbert J. Neuromyelitis Optica and Concentric Rings of Baló in the Brainstem. *Arch Neurol* 2009; 66: 274-275.
5. **Kister I**, Chamot E, Bacon JH et al. Rapid disease course in African Americans with multiple sclerosis. *Neurology* 2010 Jul 20;75(3):217-23.

6. **Kister I**, Caminero AB, Montheith TS, et al. Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. *J Pain and Headache* 2010 Oct; 11(5):417-25.
7. **Kister I**, Abbott R, Brook A, Weidenheim KM, Grosberg BM. Head Tilt in a Young Girl with Headache. *Headache* 2011;51(2):292-4.
8. **Kister I**, Chamot E, Bacon JH, Cutter G, Herbert J. Trend for Decreasing Multiple Sclerosis Severity Scores with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. *Mult Scler J* 2011 Jun;17(6):725-733.
9. **Kister I**, Munger K, Herbert J, Asherio A. Increased Risk of Multiple Sclerosis among Women with Migraine in the Nurses' Health Study II. *Mult Scler J* 2012 Jan;18(1):90-7.
10. Cabrera-Gomez JA, **Kister I**. Conventional brain MRI in neuromyelitis optica. *Eur J Neurol.* 2012 Jun;19(6):812-9.
11. Banker P, Sonni, S, **Kister I**, Loh J, Lui Y. Pencil-Thin Ependymal Enhancement in Neuromyelitis Optica Spectrum Disorders. *Mult Scler J.* 2012 Jul;18(7):1050-3.
12. Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, Van PV, Luliano G, Fiol M, Verhuel F, Barnett M, Slee M, Herbert J, **Kister I**, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray O, Butzkueven H. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. *J Neurol Neurosurg Psychiatry* 2012 Mar;83(3):305-10.
13. **Kister I**, Chamot E, Cutter G, Bacon T, Jokubaitis VG, Hughes SE et al. Increasing age at disability milestones among MS patients in the MSBase Registry. *J Neurol Sci* 2012 Jul; 318(1-2):94-99.
14. **Kister I**, Herbert J, Zhou Y, Ge Y. Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica. *Mult Scler Intern* 2013; 2013:398259-398259.
15. **Kister I**, Chamot E, Salter AR, Cutter GR, Bacon TE, Herbert J. Disability in multiple sclerosis: A reference for patients and clinicians. *Neurology* 2013; 80(11):1018-1024.
16. **Kister I**, Bacon TE, Chamot E, Salter AR, Cutter G, Kalina J, Herbert J. Natural History of Multiple Sclerosis Symptoms. *Int J MS Care* 2013 Fall; 15(3): 146-158
17. Chamot E., **Kister I**, Cutter G. Bifactor structure of clinical disability in relapsing multiple sclerosis. *Mult Scler and Related Disord.* 2014 3(2):176-185.
18. Raz E, Loh J, Saba L, Omari M, Herbert J, Lui Y, **Kister I**. Periventricular Lesions Help Differentiate Neuromyelitis Optica Spectrum Disorders from Multiple Sclerosis. *Mult Scl Intern.* 2014:986923, <http://dx.doi.org/10.1155/2014/986923>
19. Vishwanath V, Wong E, Crystal SC, Robbins MS, Filopoulos M, Lipton RB, Yazici Y, **Kister I**. Headache in Behçet's syndrome: review of literature and NYU Behçet's syndrome center experience. *Curr Pain Headache Rep.* 2014; 18(9):445.
20. **Kister I**, Kuesters G, Chamot E, Omari M, Dontas K, Yarussi M, Subramanyam M, Herbert J. IV immunoglobulin confounds JC virus antibody serostatus determination. *Neurol Neuroimmunol Neuroinflamm.* 2014 Sep 18;1(3):e29. doi: 10.1212/NXI.0000000000000029.
21. Bacon J, **Kister I**, Bacon T, Pasternak E, Strauchler Y, Herbert J. Sound Lateralization Test Distinguishes Unimpaired MS Patients from Healthy Controls. *Mult Scler Int.* 2014;2014: 462043.
22. Sarva H, Antezana A, Policard J, Rojas-Soto D; El-Sherif Y, **Kister I**, Pulitzer S, Anziska, Y. Diversity of Neuromyelitis Optica: Inner City Hospital Experience. *Journal of neurology & neurophysiology* 2014;5(2).
23. Chamot E, **Kister I**, Cutter GR. Item Response Theory-based Measure of Global Disability in Multiple Sclerosis Derived from NARCOMS Performance Scales. *BMC Neurol.* 2014 14:192.
24. Wolf NI, Toro C, **Kister I**, Latif KA, Leventer R, Pizzino A, Simons C, Abbink TE, Taft RJ, van der Knaap MS, Vanderver A. DARS-associated leukoencephalopathy can mimic a steroid-responsive neuroinflammatory disorder. *Neurology* 2015 Jan 20;84(3):226-30.

25. Antezana A, **Kister I**, Herbert J. A Case of Encephalopathy in an Immunocompetent Adult with Persistent Parvovirus B19 Viremia. *The Open Neurology Journal* 2015 9. doi: 10.2174/1874205X20150520E001
26. Bozin I, Ge Y, Kuchling J, Dusek P, Chawla S, Harms L, Ruprecht K, Niendorf T, Paul F, **Kister I**, Sinnecker T, Wuerfel J. Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration. *PLoS One*. 2015 Jul 17;10(7):e0128386. doi: 10.1371/journal.pone.0128386
27. Antezana A, Sigel S, Herbert J, **Kister I**. Natalizumab-induced hepatic injury: A case report and review of literature. *Mult Scler Relat Disord*. 2015 Nov;4(6):495-8.
28. Perumal JS*, **Kister I***, Howard J, Herbert J. Disease exacerbation after rituximab induction in neuromyelitis optica. *Neurol Neuroimmunol Neuroinflamm*. 2015 Feb 5;2(1):e61. (*First co-author).
29. Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand'Maison F, Havrdova E, Horakova D, Boz C, Oreja-Guevara C, Alroughani R, Iuliano G, Duquette P, Girard M, Terzi M, Hupperts R, Grammond P, Petersen T, Fernandez-Bolaños R, Fiol M, Pucci E, Lechner-Scott J, Verheul F, Cristiano E, Van Pesch V, Petkovska-Boskova T, Moore F, **Kister I**, Bergamaschi R, Saladino ML, Slee M, Barnett M, Amato MP, Shaw C, Shuey N, Young C, Gray O, Kappos L, Butzkueven H, Kalincik T, Jokubaitis V; MSBase study group. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. *Mult Scler J*. 2016; 22: 4520-532.
30. Charlson R, **Kister I**, Kaminetzky D, Shvartsbeyn M, Meehan SA, Mikolaenko I. CNS neutrophilic vasculitis in neuro-Sweet disease. *Neurology* 2015 Sep 1;85(9):829-30.
31. Rojas JI, Patrucco L, Trojano M, Lugaresi A, Izquierdo G, Butzkueven H, Jokubaitis V, Duquette P, Girard M, Grand'Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Petersen T, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Edite Rio M, Van Pesch V, Pia Amato M, Iuliano G, Fiol M, Slee M, Verheul F, Fernandez-Bolanos R, Poehlau D, Saladino ML, Den Braber-Moerland L, Deri N, Oleschko-Arruda W, Cabrera-Gomez JA, Paine M, Vella N, **Kister I**, et al. on behalf of the MSBase Study Group. "Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. *Mult Scl J—Experimental, Translational and Clinical* 2015;(1): 2055217315600193
32. Zhovtis Ryerson L, **Kister I**, Snuderl M, Magro C, Bielekova B. Incomplete Susac syndrome exacerbated after natalizumab. *Neurol Neuroimmunol Neuroinflamm*. 2015; 2(5):e151.
33. Fox RJ, Chamot E, Salter AR, Cutter GR, Kalina JT, Bacon TE, **Kister I**. Prevalence of MS symptoms across lifespan: data from the NARCOMS Registry. *Neurodegen Dis Manag* 5(6):3-10, DOI 10.2217/nmt.15.55
34. Zhovtis Ryerson L, Frohman TC, Foley J, **Kister I**, Weinstock-Guttman B et al. Extended interval dosing of natalizumab in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2016 Aug;87(8):885-9. doi: 10.1136/jnnp-2015-312940.
35. Green R, Kalina TJ, Pandey, K, **Kister I**. SymptoMScreen: a tool for rapid assessment of symptom severity in MS across multiple domains. *Appl Neuropsychol Adult*. 2016 Apr 14:1-7.
36. Chawla S, **Kister I**, Wuerfel J, Brisset JC, Liu S, Sinnecker T, Dusek P, Haacke EM, Paul F, Ge Y. Iron and Non-iron Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI. *AJNR Am J Neuroradiol*. 2016 Jul;37(7):1223-30.
37. Hoch MJ, Chung S, Fatterpekar GM, **Kister I**, Shepherd T. Track Density Imaging of Hypertrophic Olivary Degeneration from Multiple Sclerosis Plaque. *BJR Case Rep* 2016; 2: 20150299
38. **Kister I**, Johnson E, Raz E, Babb, J, Loh J, Shepherd TM. Specific MRI findings help distinguish acute transverse myelitis of neuromyelitis optica from spinal cord infarction. *Mult Sclerosis and Rel Disord*. 2016 9:62-67.
39. Ventura RE, **Kister I**, Chung S, Babb JS, Shepherd TM. Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. *Neurol Neuroimmunol Neuroinflamm*. 2016 Apr 14;3(3):e224.
40. Sinnecker T, Schumacher, S, Mueller K, Pache F, Dusek P, Harms L, Ruprecht K, Nytrova P, Chawla S, Niendorf T, **Kister I**, Paul F, Ge Y, Wuerfel J. MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T. *Neurol Neuroimmunol Neuroinflamm* 2016;3(4): e259.

41. Schumacher S, Pache F, Bellmann-Strobl J, Behrens J, Dusek P, Harms L, Ruprecht K, Nytrova P, Chawla S, Niendorf T, **Kister I**, Paul F, Ge Y, Wuerfel J, Sinnecker T. Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study. *MAGMA*. 2016 Jun; 29(3):535-41.
42. Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, **Kister I**, Petkovska-Boskova T, Ampapa R, Kermodé A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group. Contribution of different relapse phenotypes to disability in multiple sclerosis. *Mult Scler J*. 2017 Feb;23(2):266-276.
43. **Kister I**, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand'Maison F et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. *J Neurol Neurosurg Psychiatry*. 2016 Oct;87(10):1133-7.
44. Charlson RE, Herbert J, **Kister I**. Severity Grading in Multiple Sclerosis: A Proposal. *Int J MS Care*. 2016 Sep-Oct;18(5):265-270.
45. Zhovtis Ryerson L, R. Green, G. Confident, K. Pandey, B. Richter, T. Bacon, C. Sammarco, L. Laing, J. Kalina, I. **Kister**. Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis. *Ther Adv Neurol Disord*. 2016 Nov;9(6):454-461.
46. Ventura RE, Antezana AO, Bacon T, **Kister I**. Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans. *Mult Scler J*. 2016 Nov 29. pii: 1352458516679894.
47. **Kister I**, Corboy JR. Reducing costs while enhancing quality of care in MS. *Neurology*. 2016 Oct 11;87(15):1617-1622.
48. Richter B, Cutter G, Pandey K, Mohn J, Bacon TE, **Kister I**. Body mass index correlates with Multiple Sclerosis disease and symptom severity in women, but not in men. *Neurological Disorders and Therapeutics*. 2017 1(1): 1-5 doi: 10.15761/NDT.1000104.
49. Green R, Cutter G, Friendly M, **Kister I**. Which Symptoms Contribute the Most to Patients' Perception of Health in MS? *Mult Scler J Exp Transl Clin*. 2017 Jul-Sep; 3(3): 2055217317728301.
50. Gutman JM, Kupersmith M, Galetta S, **Kister I**. Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures. *J Neurol Sci* 2018 387: 170-173. doi.org/10.1016/j.jns.2018.01.042
51. Longbrake EE, D Kantor, S Pawate, MJ Bradshaw, MD, G Von Geldern, MD, S Chahin, AH Cross, BJ Parks , M Rice, SJ, Khoury, B Yamout, M Zeineddine, S Russell-Giller, A, Caminero-Rodriguez, K Edwards, E Lathi, D VanderKodde, W Meador, R Berkovich, L Ge, TE Bacon, **I Kister**. Effectiveness of alternate dose fingolimod for multiple sclerosis. *Neurology: Clinical practice* 2018; 8(2):102-107 doi:10.1212/CPJ.0000000000000434
52. Mealy MA, Kessler RA, Rimler Z, Reid A, Totonis L, Cutter G, **Kister I**, Levy M. Mortality in American Neuromyelitis Optica is Strongly Associated with African Ancestry. *Neurol Neuroimmunol Neuroinflamm*. 2018 Jun 7;5(4):e468. doi: 10.1212/NXI.0000000000000468. eCollection 2018 Jul.
53. Chawla S, **Kister I**, Sinnecker T , Wuerfel J , Brisset JC, Paul F , Ge Y. Longitudinal Study of Multiple Sclerosis Lesions Using Ultra-high Field (7T) Multiparametric MR Imaging. *PlosOne* (in press)
54. Gutman JM, Ki K, **Kister I***, Schwartzkop R*. Total Hip and Knee Arthroplasty in Patients with Multiple Sclerosis. In *J MS Care* (in press).
55. **Kister I**, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H. Predictors of relapse and disability progression in MS patients who

discontinue disease-modifying therapy. *J Neurol Sci.* 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

56. Fragoso YD, Sousa NAC, Alves-Leon SV, Dias RM, Pimentel MLV, Gomes S, Goncalves MVM, Stella CV, Tauil CB, Anacleto A, Spessotto CV, Correa EC, Eboni ACB, Damasceno A, Damasceno B, Farinhas JGD, Mota RSS, Nogueira EGA, Pereira VCSR, Scorcine C, Bacon T, **Kister I**. Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD). *Mult Scler Relat Disord.* 2019 Jan;27:392-396. doi: 10.1016/j.msard.2018.11.031. Epub 2018 Nov 28.
57. **Kister I**, Bacon TE, Cutter GR. Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era. *Ther Adv Neurol Disord.* 2018 Sep 11;11:1756286418793613. doi: 10.1177/1756286418793613. eCollection 2018.
58. Halteh P, **Kister I**, Shapiro L, Magro C. Linear Scleroderma “En coupe de sabre” with extensive brain involvement: Clinico-pathologic correlations and response to anti-Interleukin-6 therapy (accepted for publication).
59. Tyshkov C, Pawate S, Bradshaw MJ, Kimbrough D, Chitnis T, Gelfand J, Zhovtis Ryerson L, **Kister I**. Multiple Sclerosis and Sarcoidosis: A Case for Co-Existence. (accepted for publication).
60. Shapiro M, **Kister I**, Raz E, Loh J, Nelson PK. Spinal Dural Fistula and Anterior Spinal Artery Supply from the same Segmental Artery: Case Report of Rational Endovascular Treatment. (accepted for publication).
61. Lee AP, Riboldi GM, **Kister I**, Howard JE, Ramdhani RA. Hemiparkinsonism associated with multiple sclerosis: a case report of a causal relationship. (accepted for publication).

Reviews and Book Chapters

1. Charlson R, **Kister I**, Lipton RB. Central Neuropathic Pain – Multiple Sclerosis Related Headaches. in: Case-based diagnosis and management of headache disorders by Siva, Aksel [Ed]; Lampl, Christian [Ed]. Cham, Switzerland : Springer International Publishing; Switzerland, 2015 pp. 278-281.
2. Inglese M, **Kister I**, Gutstein H, Herbert J. Neoplasm or Demyelinating Lesion? *Applied Neurology* 2007; 3:38-40.
3. **Kister I**, Caminero AB, Herbert J, Lipton RB. Tension-type headache and migraine in multiple sclerosis. *Curr Pain Headache Rep* 2010; 14(6):441-8.
4. Zhovtis Ryerson L, Herbert J, Howard J, **Kister I**. Adult-onset spastic paraparesis: an approach to diagnostic work-up. *J Neurol Sci.* 2014 Nov 15;346(1-2):43-50. doi: 10.1016/j.jns.2014.09.015.
5. Wong E, Vishwanath V, **Kister I**. Rituximab in neuromyelitis optica: A review of literature. *World J Neurol.* 2015; 5(1):39-46.
6. Rosales D, **Kister I**. Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder. *Curr Allergy Asthma Rep.* 2016 Jun;16(6):42. doi: 10.1007/s11882-016-0619-4.
7. Gutman JM, Levy M, Galetta S, **Kister I**. Clinical Reasoning: A patient with a history of encephalomyelitis and recurrent optic neuritis. *Neurology* 2017 89(19): e231-e234.
8. **Kister I**. The Multiple Sclerosis Lesion Checklist A clinician’s guide to evaluating brain MRI in a patient with improbable multiple sclerosis. *Practical Neurology* 2018, Jul-Aug, p. 68-73.
9. Wallach AI, Magro CM, Franks AG Jr, Shapiro L, **Kister I**. Protean Neurologic Manifestations of Two Rare Dermatologic Disorders: Sweet Disease and Localized Craniofacial Scleroderma. *Curr Neurol Neurosci Rep.* 2019 Feb 12;19(3):11. doi: 10.1007/s11910-019-0929-8.

Editorials

1. **Kister I**, Paul F. Pushing the boundaries of neuromyelitis optica: does antibody make the disease? *Neurology.* 2015 Jul 14;85(2):118-9.

2. **Kister I.** Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - YES. *Mult Scler.* 2017 Aug;23(9):1188-1190. doi: 10.1177/1352458517709957.

Letters

1. **Kister I,** Herbert J, Swerdlow M, Bergamaschi R, Piccolo G, Oger J. Occurrence of CNS demyelinating disease in patients with myasthenia gravis (Letter). *Neurology.* 2007; 17;68(16):1326-7.
2. Sutaria M, Miro K, Mathew A, **Kister I,** Feigenbaum BA. Special considerations for rapid drug desensitization with natalizumab. *Journal of allergy & clinical immunology.* 2011 ;127(2 Suppl 1):AB196.
3. **Kister I,** Ge Y, Herbert J, Sinnecker T, Wuerfel J, Paul F. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution (Letter). *Neurology.* 2013 Nov 26;81(22):1966.
4. Vollbracht S, Robbins M, **Kister, I.** Classification challenge in migrainous infarction. *Headache.* 2014 Jan;54(1):170-171.
5. Antezana A, Herbert, J, Park J, **Kister I.** Glatiramer Acetate - induced Hepatotoxicity in a Patient Naive to Interferon Beta. (Letter). *Neurology* 2014;82(20):1846-7
6. **Kister I** and Corboy J. Author response: Reducing costs while enhancing quality of care in MS. *Neurology.* 2017;88(12):1212-1212.DOI:10.1212/WNL.0000000000003756

Oral Presentations at National and International Conferences

- 2010 "Cross-Sectional Survey of Neurologic Dysfunction and Headaches in North American Patients with Behçet's Disease." **Kister I** et al. Presented at the 62nd Annual Meeting of the American Academy of Neurology Annual Meeting, Toronto, Canada
- 2010 "Brain MRI in a Series of NMO IgG Seropositive Patients." **Kister I** et al. Presented at the 26th Annual Meeting of the European Congress for Research and Treatment of Multiple Sclerosis, Gothenburg, Sweden
- 2011 "Subacute Amotivational Syndrome as the Only Symptom of Progressive Multifocal Leukoencephalopathy in a Natalizumab-Treated Multiple Sclerosis Patient." Babinski, K; Howard, J; Gottschalk, C; Herbert, J; **Kister, I.** Presented at the 63rd Annual AAN Annual Meeting, Honolulu, HI.
- 2015 "Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants." **Kister, I** et al. European Congress for Research and Treatment of Multiple Sclerosis 37th Annual Meeting, Barcelona, Spain
- 2016 "Is there cervical spinal cord atrophy in NMOSD without myelitis?" R.E. Ventura, S. Chung, J.S. Babb, T.M. Shepherd, I. **Kister.** 8th Guthy Jackson Charitable Foundation Roundtable, Los Angeles
- 2017 "Alternate dosing of fingolimod for Multiple Sclerosis." **Kister I** et al. Presented at the 69th Annual AAN Annual Meeting, April 25, 2017, Boston MA

Poster Presentations at National and International Conferences

1. **Kister I,** Herbert J. Three cases of herpes reactivation in MS patients on Natalizumab monotherapy (abstract). *Multiple Sclerosis* 2007; 13 (suppl.2):S167.
2. **Kister I,** Herbert, J, Fromm T, Lipton R. Impact of headaches on the course of multiple sclerosis: preliminary results of a cross-sectional survey (abstract). *Mult Scler* 2007; 13 (suppl.2):S123.
3. **Kister I,** Herbert J. Localized scleroderma with enhancing brain lesions mimicking multiple sclerosis: a case report and literature review. *Mult Scler.* 2007; 13(16): S225.
4. Herbert J, Kappos L, Giovanonni G, Havrdova E, Hutchinson M, Lublin F, Miller D, O'Connor P, Phillipis JT, Polman CH, Wajgt A, Bacon J, **Kister I,** Pace A, Panzara M. Impact of natalizumab on multiple sclerosis severity: analysis of patients and subgroups from AFFIRM study using the Multiple Sclerosis Severity Scale (abstract). *Mult Scler* 2007;13 (suppl.2):S169.
5. Herbert J, Kappos L, Calabresi P, Confavreux C, Galetta S, Giovannoni G, Havrdova E, Hutchinson M, Lublin F, Miller D, O'Connor P, Phillips J, Radue C, Rudick R, Stuart W, Wajgt A, Guttman W, Wynn G, Bacon J,

- Kister I**, Pace A, Panzara M. Natalizumab Reduces Multiple Sclerosis Severity: Analysis of Patients from the AFFIRM and SENTINEL Studies Using the Multiple Sclerosis Severity Scale (abstract). *Neurology* 2008;70(suppl.1):A212.
6. **Kister I**, Bacon J, et al. MS Severity Scores in African Americans Are Dramatically Worse than Non-African Americans: Analysis of the New York State MS Consortium (NYSMSC) Dataset (abstract) *Neurology* 2008;70(suppl.1):A332.
 7. Mihai C, Teter B, Weinstock-Guttman B, Christodoulou C, Coyle P, Drake A, Frontera A, Gauthier S, Goodman A, Gottesman M, Granger C, Herbert J, Holub R, Jubelt B, Khan M, **Kister I**, Krupp L, Lava N, Lenihan M, Lublin F, Miller A, Nealon N, Schwid S, Smiraldo J, Snyder D, Tullman M, Zivadinov R, Munschauer F. Predictors of Marital Disruption in Multiple Sclerosis (abstract). *Neurology* 2008;70(suppl.1):A336.
 8. Anbarasan D, **Kister I**, Herbert J. Worsening of lupus symptoms after IFN-b1a injections in a patient with multiple sclerosis and systemic lupus erythematosus modifying therapies. There was no significant difference in neurological (abstract). *Mult Scler* 2008 14 (suppl 1): S52.
 9. **Kister I**, Herbert J. Electrophysiologically-eloquent pontine inflammatory lesion causes reversible loss of wave V on brainstem auditory evoked response (abstract). *Mult Scler* 2008 14 (suppl 1): S52.
 10. **Kister I**, Caminero A, Montheith T, Soliman A, Fromm J.T., Bacon J., Lipton R.B., Herbert J. Threefold increase in Migraine in MS Patients Compared to Age- and Gender-matched Population Controls (abstract). *Neurology* 2009; 72(S3):A373.
 11. Teter B, Weinstock-Guttman B, Mihai C, Apatoff B, Coyle P, Gauthier S, Goodman A, Gottesman M, Granger C, Herbert J, Holub R, Jubelt B, **Kister I**, Krupp L, Lenihan M, Lublin F, Miller A, Nealon N, Perel A, Schwid S, Snyder D, Tullman M, Zivadinov R, Munschauer F. Parity, education and sun exposure may predict long-term disability in female patients with multiple sclerosis. *Mult Scler.* 2008 Sep; 14(1): S203.
 12. Mihai C, Teter B, Weinstock-Guttman B, Apatoff B, Coyle P, Batra N, Drake AS, Gauthier S, Goodman A, Gottesman M, Herbert J, Holub R, Jubelt B, **Kister I**, Krupp L, Lenihan M, Lublin F, Miller A, Nealon N, Perel A, Schwid S, Snyder D, Tullman M, Zivadinov R, Munschauer F. Sex differences related to marital status in patients with multiple sclerosis. *Mult Scler.* 2008 Sep; 14(1): S193
 13. Graber JJ, **Kister I**, Gruber M, Warren F, Weinberg H, Neophytides A, Inglese M, Zagzag D, Herbert J. Idiopathic tumefactive demyelinating lesions: initial characteristics predict subsequent relapsing-remitting multiple sclerosis (abstract). *Neurology* 2009; 72(S3):A78.
 14. Howard J, Holst B, **Kister I**, et al. MRI and Clinical Characteristics of African versus Caucasian Americans with MS (abstract). *Multiple Sclerosis* 2009; 15: S151–S269.
 15. Robbins MS, Crystal SC, Filopoulos M, **Kister I**, Bacon T, Lipton RB, Yazici Y. Chronic Daily Headache in North American Patients with Behçet’s Disease (abstract). *Headache* 2010; 50(S1):16.
 16. George R, Camacho-Halili M, **Kister I**, Herbert J, Gottesman M, Davis-Lorton M. Successful induction of tolerance to Tysabri (R) (Natalizumab) after a prior hypersensitivity reaction. *Annals of allergy, asthma & immunology.* 2009; 103(5):A105-A105.
 17. Mihai C, Teter B, Apatoff B, Coyle P, Gauthier S, Goodman A, Gottesman M, Granger C, Herbert J, Lawn F, Holub R, Jubelt B, **Kister I**, Krupp L, Lenihan M, Lublin F, Miller A, Munschauer F, Perel A, Schwid S, Snyder D, Tullman M, Zivadinov R, Weinstock-Guttman B. Characteristics and Predictive Factors of Disability Outcomes of Multiple Sclerosis Patients with 5-Year Use of Initial Disease Modifying Therapy. *Neurology.* 2009; 71(11):A82-A82.
 18. Teter B, Mihai C, Wasch S, Apatoff B, Coyle P, Gauthier S, Goodman A, Gottesman M, Granger C, Herbert J, Lawn F, Holub R, Jubelt B, **Kister I**, Krupp L, Lenihan M, Lublin F, Miller A, Munschauer F, Perel A, Snyder D, Tullman M, Zivadinov R, Weinstock-Guttman B. Physician Disease Modifying Therapy Decisions for Patients Registered with the New York State Multiple Sclerosis Consortium (NYSMSC). *Neurology* 2009; 72(11): A316-A316.

19. Crystal SC, Robbins MS, Filopoulous M, **Kister I**, Lipton RB, Yazici Y. Headache in North American Patients with Behçet's Disease (abstract). *Headache* 2010; 50(S1):20.
20. Bacon J, Bacon T, **Kister I**, Herbert J. A Novel Computerized Word-Naming Test Shows That Crossed-Hemisphere Processing Speed Is Slowed in Multiple Sclerosis Patients (abstract). *Neurology* 2010
21. Herbert J, Chamot E, Bacon J, Apatoff B, Blitz K, Coyle P, Goodman A, Gottesman M, Edwards K, Frontera A, Holub R, Jubelt B, Khan M, Krupp L, Lenihan M, Lublin F, Mihai C, Miller A, Munschauer F, Perel A, Snyder D, Teter B, Tullman M, Weinstock-Guttman B, Zivadinov R, Kister, I. Trend Towards Lowering of Multiple Sclerosis Severity Scores Among More Recent Enrollees Into the New York State Multiple Sclerosis Consortium (abstract). *Neurology* 2010
22. **Kister I**, Munger K, Herbert J, Ascherio A. Increased Risk of Multiple Sclerosis among Women with Migraine in the Nurses' Health Study II (abstract). *Neurology*. 2010;74(9):A63-A63.
23. Filopoulos M; Robbins MS; Crystal SC; **Kister I**; Bacon T; Lipton; Labitigan M; Yazici Y. Headache in North American Patients with Behcet's Syndrome: Common and important cause of disability. *Annals of the rheumatic diseases*. 2010;69:S3.
24. Perumal J, **Kister I**, Howard J, Herbert J. Paradoxical response after rituximab infusion in patients with neuromyelitis optica. *Multiple Sclerosis* 2010;16(S10):P855
25. **Kister I**, Bacon T, Chamot R, Cutter G, Butzkueven H, Herbert J. on behalf of MSBase Registry. Multiple Sclerosis Severity Scores decrease with calendar year of first EDSS assignment in MSBase. *Multiple Sclerosis* 2010;16(S10):P609
26. Chamot E, **Kister I**, Herbert J, Cutter GR. Challenges in Analysis of Calendar Trends in Multiple Sclerosis Disability and Severity Scores as Indirect Evidence of Treatment Benefit. The Consortium of Multiple Sclerosis Centers Annual Meeting, San Antonio, Texas, 2010.
27. **Kister I**, Sathe S, Zeng BJ, Howard J, Kiproviski K, Herbert J, Hays A. Adult Polyglucosan Body Disease with Muscle Involvement . *Neurology* 2011; 76(S4): A284
28. **Kister I**, Bacon T, Chamot E, Cutter H, Bacon J, Herbert J. et al. Decrease in Individual Multiple Sclerosis Severity Scores during Follow-Up Period: Analysis of the New York State Multiple Sclerosis Consortium Dataset. *Neurology* 2011; 76 (S4):A604
29. Perumal JS, Laing L, Gazivoda KS, Babinski K, Howard J, **Kister I**, Herbert J. Efficacy of Natalizumab in African American Multiple Sclerosis Patients. *Neurology* 2011;76(S4): A474
30. Perumal JS, Foo FY, Cook P, Sammarco C, **Kister I**, Khan O, Herbert J. Subcutaneous Administration of Alemtuzumab (CampaTh) in Fulminant Multiple Sclerosis. *Neurology* 2011; 76(S4):A67.
31. **Kister I**, Filopoulos M, Labitigan M, Crystal S, Robbins M, Herbert J, Yazici Y. Cross-Sectional survey of Neurologic and psychiatric symptoms in North American patients with Behçet's Syndrome. *Clinical & experimental rheumatology*. 2010 Jul-Aug; 28(4):S112-S113.
32. Babinski K, **Kister I**, Laing L, Minetti J, Dontas K, Herbert J. Cardiotoxicity in Multiple Sclerosis Patients Treated with Less Than Half the Maximum Allowed Lifetime Dose (70 mg/m²) of Mitoxantrone . *Neurology* 2011; 76(S4): A248
33. Teter, B., Apatoff, B., Coyle, P., Edwards, K., Goodman, A., Gottesman, M., Granger, C., Herbert, J., Jubelt, B., **Kister, I.**, Krupp, L., Lenihan, M., Lublin, F., Miller, A., Ostroff, J., Perel, A., Snyder, D., Tullman, M., Zivadinov, R., Weinstock-Guttman, B. Capture of Patient-Perceived Negative Mood Traits to Improve Treatment for Patients with Multiple Sclerosis. *Neurology* 2011; 76(S4): A71
34. Crystal, S.C., Robbins, M.S., Filopoulos, M.T., **Kister, I.**, Lipton, R.B., Yazici, Y. Episodic Headache in North American Patients with Behçet's Disease. *Neurology* 2011; 76(S4): A199
35. Teter, B., Apatoff, B., Coyle, P., Edwards, K., Goodman, A., Gottesman, M., Granger, C., Herbert, J., Jubelt, B., **Kister, I.**, Krupp, L., Lenihan, M., Miller, A., Perel, A., Snyder, D., Tullman, M., Zivadinov, R., Weinstock-Guttman, B. Pregnancy Related to Disability Outcomes for Women with Progressive Multiple Sclerosis. *Neurology* 2011; 76(S4): A610

36. Cabrera-Gomez J, **Kister I**. Conventional Brain Magnetic Resonance Imaging in Neuromyelitis Optica. *Int J MS Care*. 2011;13(suppl 3):35
37. Babinski K, Herbert J, **Kister I**. Is there an association between hepatitis C and neuromyelitis spectrum disorder? A report of three cases. *Int J MS Care*. 2011;13(suppl 3):45.
38. Chamot E, **Kister I**, Herbert J, Cutter C Unifying Interpretation of Measures of Multiple Sclerosis Progression in Clinical Trials. *Int J MS Care*. 2011;13(suppl 3):62
39. Chamot E, **Kister I**, Cutter GR. Item Response Theory (IRT) Methodology can be used to place common clinical measures of multiple sclerosis progression on a single linear scale of general neurological disability. *Mult Scler*. 2012 Sep; 18(9):S21-S22.
40. Zhovtis S, Howard J, Herbert J, **Kister I**. Differential Diagnosis of Adult-Onset Chronic Myelopathy: MRI-Based Approach. *Neurology (abstract)*. 2012 Apr; 78 1.
41. **Kister I**, Chamot E, Salter A, Cutter G, Bacon T, Kalina J, Herbert J. Natural History of MS Symptoms: Perceived Disease Impact across Disease Span in Nine Neurologic Domains among Enrollees in North American Research Committee on Multiple Sclerosis (NARCOMS) Registry (abstract). *Neurology*. 2012 Apr; 78 1.
42. **Kister, I**; Herbert, J; Zhou, Y; Ge, Y.. Ultra-high-field (7T) magnetic resonance imaging of brain lesions of neuromyelitis optica spectrum disorders and multiple sclerosis: A case-control study [Meeting Abstract]. *Multiple sclerosis*. 2012;18(4):290-291.
43. Ryerson-Zhovtis, L; Herbert, J; **Kister, I**. A practical algorithm for differentiating neurosarcoidosis from multiple sclerosis with application to cases from NYU MS Centre [Meeting Abstract]. *Multiple sclerosis*. 2012;18:280-281.
44. Bacon, J H; Bacon, T E; **Kister, I**; Strauchler; Tsikhanovski, Bochner G; Omari, M; Bochkanova, A; Herbert, J. Backward masking paradigm captures delays in speed of processing in multiple sclerosis on a millisecond scale [Meeting Abstract]. *Multiple sclerosis*. 2012;18(4):105-106.
45. **Kister I**, Herbert J, Ge Y. Ultra-High-Field MR Imaging of Brain Lesions of Neuromyelitis Optica Spectrum Disorders (NMOsd): Absence of Central Venule within Lesions May Help Differentiate NMOsd from Multiple Sclerosis (abstract). *Neurology*. 2012 Apr; 78 1.
46. **Kister, I**; Chamot, E; Cutter, G; Salter, A; Bacon, T E; Herbert, J. Patient-determined MS Severity Scale: Ranking disease severity based on patient-rated disability [Meeting Abstract]. *Multiple sclerosis*. 2012;18(4):333-334.
47. Bacon, J H; Bacon, T E; **Kister, I**; Strauchler, Y; Tsikhanovski, Bochner G; Omari, M; Bochkanova, A; Herbert, J. A sound localisation test discriminates between controls and multiple sclerosis patients with no measurable disability [Meeting Abstract]. *Multiple sclerosis*. 2012;18(4):280.
48. Raz E, **Kister I**, Omari M, Herbert J, Lui Y, Loh J. Periependymal Abnormalities in Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis: A Case-Control Study (abstract). *Neurology*. 2012 Apr; 78 1.
49. Antezana A, Chamot E, Cutter G, Herbert J, Bacon TE, **Kister I**. Comparing Disability of Multiple Sclerosis Cohort in a Tertiary Clinic and Volunteer North American Research Committee on Multiple Sclerosis Registry Using Patient-Derived Multiple Sclerosis Severity Score. Presented at the American Academy of Neurology 66th Annual Meeting, April 26 to May 3, 2014, Philadelphia, PA
50. Antezana A, Herbert J, **Kister I**. Cognitive Deficits, Cerebrospinal Fluid Pleocytosis and White Matter Lesions Following Parvovirus B19 Infection in an Immunocompetent Adult. Presented at the American Academy of Neurology 66th Annual Meeting, April 26 to May 3, 2014, Philadelphia, PA
51. Pandey, K; **Kister, I**; Herbert, J. Multiple sclerosis in patients with common variable immunodeficiency disease: co-incidence or consequence? [Meeting Abstract], *Multiple sclerosis*. 2014;20:152-153.
52. Ge, Y; Sheng, H; Chawla, S; **Kister, I**; Herbert, J; Grossman, RI. Cellular and microstructural changes due to iron deposition in multiple sclerosis lesions [Meeting Abstract], *Multiple sclerosis*. 2014;20:297.

53. **Kister, I**; Bacon, T; Alroughani, R; Boz, C; Cristiano, E; Iuliano, G; Marriott, M; Olascoaga, J; Pucci, E; Rojas, JI; Taylor, B; Terzi, M; Vucic, S; Herbert, J; Butzkueven, H. NMOBase is a Web-based, global observational registry for an 'orphan' disorder: neuromyelitis optica [Meeting Abstract]. *Multiple sclerosis*. 2014;20:165.
54. Ramien, C; Sinnecker, T; Ge, Y; Herbert, J; Paul, F; **Kister, I**; Wuerfel, J. Neuromyelitis optica does not impact periventricular venous density - a 7 Tesla MRI study [Meeting Abstract]. *Multiple sclerosis*. 2014;20:345-345.
55. Bacon, T; **Kister, I**; Chamot, E; Cutter, G; Salter, A; Antezana, AO; Herbert, J. Using patient-derived multiple sclerosis severity score to demonstrate differences in MS severity across racial groups in an urban MS center [Meeting Abstract]. *Multiple sclerosis*. 2014;20:227-227.
56. Bacon, J; Bacon, T; **Kister, I**; Herbert, J. Transfer of information across the corpus callosum is slowed in patients with multiple sclerosis compared to healthy controls [Meeting Abstract]. *Multiple sclerosis*. 2014;20:132.
57. Herbert J, Zhovtis L, Torontore C, Foley J, Winstock-Guttman B., **Kister I** et al. Multicenter retrospective study of extended dosing of Natalizumab in Multiple Sclerosis: a strategy for mitigating risk of Progressive Multifocal Leukoencephalopathy while Maintaining Efficacy?" Presented at the American Academy of Neurology 66th Annual Meeting, April 26 to May 3, 2014, Philadelphia, PA
58. Bacon, J; Bacon, T; Rimler, Z; **Kister, I**. The sound lateralization test demonstrates slowed processing speed in MS patients with minimal to mild disability and shows no learning effects in multiple testing sessions over a 1-year period [Meeting Abstract]. *Multiple sclerosis*. 2015;21:368-368.
59. Mowry, EM; Bermel, R; Balcer, LJ; Cassard, SD; Fisher, E; Izbudak, I; Jones, S; **Kister, I**; Krueger, G; Lui, YW; Perryman, J; Sickert, D; Williams, JR; Rudick, R. Harnessing real-time patient data to improve clinical outcomes and research: the multiple sclerosis partners advancing technology and healthcare solutions (MS PATHS) initiative [Meeting Abstract]. *Multiple sclerosis*. 2015;21:411.
60. **Kister, I**; Bacon, T; Levinas, M; Green, R; Cutter, G; Chamot, E. 'Stability and prognostic utility of patient-derived MS severity score (P-MSSS) among MS clinic patients'. *Multiple Sclerosis*. 2015 [Meeting Abstract]
61. **Kister, I**; Dadon, K; Fox, M; Chawla, S; Dusek, P; Wuerfel, J; Paul, F; Sinnecker, T; Ge, Y. Longitudinal ultra-high field MRI study of brain lesions in neuromyelitis optica. *Multiple Sclerosis*. 2015 [Meeting Abstract]
62. Schumacher, S; Pache, F; Behrens, J; Dusek, P; Harms, L; Ruprecht, K; Nytrova, P; Chawla, S; Niendorf, T, **Kister, I**; Paul, F; Ge, Y; Würfel, J; Sinnecker, T. 'Periventricular venous density is normal in neuromyelitis optica - preliminary data from a 7T MRI study'. *Multiple Sclerosis*. 2015 [Meeting Abstract]
63. Ge, Y; Marshall, O; Pape, L; Lu, H; Kister, I; Grossman, R.I. 'Disrupted blood flow modulation in functional brain networks in multiple sclerosis measured with hypercapnia MRI'. *Multiple Sclerosis*. 2015 [Meeting Abstract]
64. Ge, Y; Marshall, O; Kister, I; Lu, H; Sadowski, M; Grossman, R.I. 'Assessment of whole brain blood flow changes in multiple sclerosis: phase contrast MRI versus ASL'. *Multiple Sclerosis*. 2015 [Meeting Abstract]
65. Ryerson Zhovtis L; Pandey, K; Sammarco, C; Laing, L; Confident, G; Green, R; Richter, B; Elyashiv, M; Kalina, J; **Kister, I**. Comparing dimethyl fumarate efficacy and tolerability among Caucasian-, African- and Hispanic-American MS patients'. *Multiple Sclerosis*. 2015 [Meeting Abstract]
66. Green, R; Kalina, J; Pandey, K; **Kister, I**. SymptoMScreen: a novel tool for rapidly assessing MS symptom severity in 11 domains. *Multiple sclerosis*. 2015;21:663-663.
62. Pandey KS, Cutter G, Green R, **Kister I**, Herbert J. Single-question patient-reported disability strongly correlates with Expanded Disability Status Scale. Oral presentation at 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, Spain, 2015
67. Ryerson Zhovtis L, **Kister I**, Foley, J, Remington, G et al. Extending natalizumab treatment up to eight weeks shown safe and effective in patients with multiple sclerosis: updated analysis from an ongoing multicenter study. *Multiple Sclerosis*. 2015 [Meeting Abstract]
68. Fallon J, **Kister I**, Zhovtis Ryerson, L. No Difference in Disability Progression of MS Patients Treated with Extended Interval vs. Standard Interval Natalizumab. AAN 2016 Annual meeting, Boston, MA

69. Green, R, **Kister I**. Which Symptoms Correlate the Most to Health-Related Quality of Life (HRQoL) in MS? AAN 2016 Annual meeting, Boston, MA
70. Richter B., Bacon, T., **Kister I**. Body Mass Index Is Modestly Correlated with Disease Severity in Multiple Sclerosis. AAN 2016 Annual meeting, Boston, MA
71. **I Kister**, S Chawla, J.T Wuerfel, T Sinnecker, F Paul, Y Ge. Longitudinal study of MS lesions using multi-parametric ultra-high field (7Tesla) MRI. ECTRIMS Annual meeting, Sept., 2017, London, United Kingdom
72. **I Kister**, T Spelman et al. for the MSBase Investigators. Effect of pregnancy on disease course in progressive MS: a case-control study. *Multiple sclerosis*. 2016;22:506-508.
73. Ryerson-Zhovtis, L; Ruggero, C; Rasia, S; Foley, J; **Kister, I**; Frohman, T; Weinstock-Guttman, B; Pandey, K; Pawate, S; Bomprezzi, R; Tornatore, C; Okuda, D; Smith, D; Estrada-Zuniga, G; Jacob, A; Hoyt, T; Frohman, E. Extended interval dosing for natalizumab continues to show excellent efficacy and safety: Italian experience comparison to USA data [Meeting Abstract]. *Multiple sclerosis*. 2016;22:797-798.
74. Cook, LJ; Rose, JW; Alvey, J; Jolley, AM; Kuhn, R; Marron, B; Pederson, M; Enriquez, R; Yearley, J; Dean, JM; Han, MH; Feng, M; Ganaway, T; Levy, M; Mealy, M; Coleman, J; Salvatore, M; Beneett, J; Johnson, R; Hsu, E; Traboulsee, A; Carruthers, R; Lee, A; Shubert, J; McMullen, K; **Kister, I**; Rimler, Z; Reid, A; Green, R; Kenneally, M; Rodriguez, R; Behne, D; Blackway, D; Coords, B; Blaschke, T; Smith, TJ; Yeaman, MR; Behne, J; Guthy-Jackson Charitable Fdn Int C. A comparison of seropositive and seronegative patients in the Collaborative International Research in Clinical and Longitudinal Experience for NMOSD Studies (CIRCLES) registry [Meeting Abstract]. *Multiple sclerosis*. 2016;22:852-853.
75. Green, R; Nathanson, J; **Kister, I**. Multi-dimensional assessment of symptom severity in matched NMO and MS patients [Meeting Abstract]. *Multiple sclerosis*. 2016;22:126-127.
76. **Kister, I**; Bacon, T; Shaygannejad, V; Hor, J Y; Alroughani, R; Haas, S et al. Prospectively tracking disease course and treatment changes in neuromyelitis optica using NMOBase, a global online registry [Meeting Abstract]. *Neurology*. 2016;86(16).
77. Hainline C., Rizzo J.R., Hudson T., Dai W., Joel B., Nolan R., Hasanaj L., Balcer L., Galetta S., **Kister I**. and Rucker J., 2016. Capturing the Efferent Side of Vision in Multiple Sclerosis: New Data from a Digitized Rapid Number Naming Task (P6. 317). *Neurology*, 86(16 Supplement), pp.P6-317.
78. Gutman, J; Schwarzkopf, R; **Kister, I**. Total hip and knee arthroplasty in multiple sclerosis patients: The NYU experience. *Neurology* April 18, 2017 vol. 88 no. 16 Supplement P3.376
79. Ryerson, L Z; Foley, J; **Kister, I** et al. Exploratory PML risk assessment on extended interval natalizumab dosing. AAN 2017 Annual meeting, Boston, MA
80. Ryerson, L Z; Monaco, M C; **Kister, I** et al. Effect of extended interval dose natalizumab therapy on CD19+ and CD34+ cell mobilization from bone marrow and JC Viremia. AAN 2017 Annual meeting, Boston, MA
81. Gutman, J., Fouladvand, M., Jafar, J., Jain, R., & **Kister, I**. Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies in a Patient with Ataxia, Diplopia, and an Enhancing Cerebellar Lesion. AAN 2018 Annual meeting, Los Angeles, CA.
82. **Kister, I**, Bacon, T., Shaygannejad, V., Havrdova, E., Alroughani, R., Terzi, M., et al. Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry. AAN 2018 Annual meeting, Los Angeles, CA.
83. Gutman, J., Ryerson, L. Z., & **Kister, I**. A Case of Progressive Multifocal Leukoencephalopathy in a Patient on Extended Interval Dose Natalizumab. AAN 2018 Annual meeting, Los Angeles, CA.
84. Ryerson, L. Z., Foley, J., Chang, I., **Kister, I**, Cutter, G., Metzger, R., et al. Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program. The Australian & New Zealand Association of Neurologists (ANZAN) 2018 Annual Conference.
85. Amezcua, L., Cook, L., Yeaman, M., **Kister, I**, & Levy, M. Black race is an independent risk factor for disability in neuromyelitis optica spectrum disorder. ECTRIMS 2018, London, England.

86. **Kister, I.**, Hartung, H. P., Vermersch, P., Buffels, R., Kuhelj, R., McDougall, F., ... & Cutter, G. Patient-reported SymptoMScreen baseline scores in patients with relapsing-remitting multiple sclerosis enrolled in Phase IIIb studies of ocrelizumab (ENSEMBLE and CASTING). In ECTRIMS 2018, London, England.
87. **Kister, I.**, Bacon, T., & Cutter, G. (2018, October). Tracking symptom impact in MS patients: longitudinal study of symptoMScreen scores in patients attending two large tertiary MS centers. ECTRIMS 2018, London, England.

Extramural Sponsorship

Current

- 2013 - present Using a novel, patient-rated disease severity score to track disability progression in 'real life' MS practice
Genzyme
Role: PI
- 2013 - present A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis
Novartis
Role: site PI
- 2015 - present Ethnic Variability of the Gastrointestinal Microbiome in Multiple sclerosis
EMD Serono
Role: PI
- 2014 - present MSBase: An International Platform Dedicated to Linking Multiple Sclerosis (MS) Researchers
MSBase Foundation
Role: Site PI
- 2014 - present Brain Oxygen Metabolism and Hemodynamic Impairment in Multiple Sclerosis
National Institute of Health (5R01NS076588-04)
Role: Co-I
- 2015 - present Mesoscopic Biomarkers of Neurodegeneration with Diffusion MRI
National Institute of Health (5R01NS088040-03)
Role: Co-I
- 2015 - present Collaborative International Research in Clinical and Longitudinal Experience in NMO Studies
Guthy-Jackson Charitable Foundation
Role: Site PI
- 2016 - present The PREVENT Study, a large-scale registration study for a potential medication (eculizumab) for relapsing Neuromyelitis Optica Spectrum Disorders (NMOSD)
Alexion
Role: Site PI
- 2016 - present Pharmacokinetics of Natalizumab Patients on Extended Dosing Schedules
Role: Site PI
- 2017-present
- 2016 - present Retrospective Chart Review of Extended Interval Dosing Schedules for Natalizumab (Tysabri) Patients Diagnosed with Multiple Sclerosis
Role: Site PI
- 2016 - present Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

Patient-Centered Outcomes Research Institute

Role: Site PI

2017-present

2017 - present

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) (POINT)

Actelion

Role: Site PI

Previous

2006 - 2014

The African American Multiple Sclerosis Genetic Susceptibility Project

UCSF

Role: PI

2007 - 2008

Prevalence and significance of migraines and other headaches in MS

NMSS

Role: Co-PI

2007 - 2011

A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis

TEVA Neuroscience

Role: Co-I

2007 - 2011

A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis (CAMMS 323)

Genzyme

Role: Co-I

2007 - 2011

A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients with Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy (CAMMS 324)

Genzyme

Role: Co-I

2007 - 2012

A 24-month double-blind, randomized, multi-center, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis

Novartis

Role: Co-I

2008 - 2010

Assessment of cognitive processing speed in Multiple Sclerosis

Bayer Inc.

Role: Co-PI

2010 - 2012

Development and application of an MS severity scale using patient-derived metrics of disease progression

NMSS

Role: PI

2010 - 2014	Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy; Protocol Number: 101JC403 Biogen Idec Role: PI
2011 - 2012	Can Neuromyelitis Optica be differentiated from 'conventional' Multiple Sclerosis with ultra-high field brain imaging? Guthy-Jackson Charitable Foundation Role: PI
2011 - 2013	DER-401: Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg twice daily) in Patients with Multiple Sclerosis Acorda Role: Co-I
2010 - 2015	MSComet: A Phase IV, observational, open label, multinational, multicenter study to collect clinical efficacy data in up to 1, 000 patients with active Relapsing Remitting Multiple Sclerosis currently treated with beta-interferon or glatiramer acetate. MSBase Foundation Role: Co-I
2011 - 2013	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis Avanir Role: Co-I
2013 - 2014	Identifying MS patients at risk for severe disease using information provided by patients: P-MSSS-based approach Biogen Idec Role: PI
2013 - 2014	Implication of Intravenous Immunoglobulin therapy in JCV Ab Testing Biogen Idec Role: PI
2013 - 2015	A Novel, Sensitive, Technically-Simple Sound Localization Test to Detect and Monitor Disease Progression in Minimally Affected Multiple Sclerosis Patients EMD Serono Role: Co-I
2013 - 2015	Cerebral ultra-high field MR imaging in Neuromyelitis Optica: US-German longitudinal study NMSS Role: PI
2010 - 2015	JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri®: STRATIFY-2 Biogen Idec Role: PI
2013 - 2015	A 12-month, prospective, randomized, active-controlled, open-label study to evaluate the patient retention of Fingolimod vs. approved first-line disease modifying therapies in adults who are in early stages of treatment for relapsing remitting multiple Sclerosis (PREFERMS) Novartis

2010 - 2015	<p>Role: Co-I</p> <p>An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme Sponsored Studies of Alemtuzumab</p> <p>Genzyme</p> <p>Role: PI</p>
2011 - 2015	<p>A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis</p> <p>Roche</p> <p>Role: PI</p>
2015 - 2016	<p>Retrospective chart review patient on Fingolimod</p> <p>IMS Health</p> <p>Role: PI</p>
2015 - 2016	<p>TRANSITION: A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod</p> <p>Novartis</p> <p>Role: Co-I</p>
2013 - 2015	<p>Cerebral ultra-high field MR imaging in Neuromyelitis Optica: US-German longitudinal study</p> <p>Guthy-Jackson Charitable Foundation</p> <p>Role: PI</p>
2014 - 2017	<p>MS-LAQ-301E - A Multinational, Multicenter, Open-Label, Single-Assignment Extension of the MS-LAQ-301 (ALLEGRO) Study, to Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects with Relapsing Multiple Sclerosis.</p> <p>Teva Pharmaceuticals</p> <p>Role: site PI</p>
2014 - 2017	<p>A multicenter, open-label, extension study to evaluate the long-term safety and efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), monotherapy in subjects with multiple sclerosis who have completed study 205MS301</p> <p>Biogen Idec</p> <p>Role: Co-I</p>

Teaching

Teaching Experience

2009 - 2010	Preceptor for Neurology Rotation for 3rd Year medical students, NYU School of Medicine
2011 - present	Introductory lectures on MS and NMO for Neurology residents, NYU School of Medicine

Mentoring

Advisees

2017 – 2018	Asya Wallach, MD, clinical fellow
2017 – 2018	Charles Tyshkov, MD, clinical fellow, Currently Attending at Weil Cornell, NY
2016 - 2017	Joseph Gutman, MD, clinical fellow, Currently Attending at Winthrop and NYU
2015 - 2016	Clotilde Hainline, MD clinical fellow, Currently Attending at Boston University

2015 - 2016 Dominique Rosales, MD, clinical fellow, Currently Attending at Wake Forest Baptist Multiple Sclerosis Center, Winston-Salem, NC
2014 - 2015 Rachel Ventura, MD, PhD, clinical fellow,
2014 - 2015 Erik Charlson, MD, clinical fellow, Currently Assistant Professor at NYU
2013 - 2014 Ariel Antezana, MD, clinical fellow, Currently Neurologist in private practice
2011 - 2012 Lana Zhovtis, MD, clinical fellow, Currently Assistant Professor at NYU
2010 - 2011 Kristen Babinski, MD, PhD, clinical fellow, Currently Attending at NY Methodist
2009 - 2010 Yakov Isakov, DO, clinical fellow, Currently Neurologist, private practice
2009 - 2010 Jonathan Howard, MD, clinical fellow, Currently Assistant Professor at NYU

Educational Program Building/Leadership

2011 - present Director, Neuroimmunology Fellowship, NYU School of Medicine

Educational Extramural Funding

2010 - 2017 PI on awards for NYU Multiple Sclerosis Fellowship from Biogen-Idec (2011, 2012, 2014, 2015, 2016, 2017, 2018) and National Multiple sclerosis Society (2013, 2014)

Certification

2006 - present New York State Medical license
2009 - present New Jersey State Medical license

Clinical Service Responsibilities

2007 – 2011 Consulting Physician, Neuro-rehabilitation Unit, NYU Langone Medical Center
2007 – present Attending, NYU MS Care Center, NYU Langone Medical Center
2010 – present Attending, Barnabas MS Care Center, Barnabas-RWJ, Livingston, NJ
2013 – present Neurology Inpatient Consult Attending, NYU Langone Medical Center

Clinical Program Building/Leadership

Jan 2015 - Sep 2015 Interim Director, NYU Multiple Sclerosis Comprehensive Care Center
2016 - present Director, Neuromyelitis Optica Program, NYU School of Medicine

Editorial Activities

Ad hoc reviewer for
Neurology
Neurology: Neuroimmunology & Neuroinflammation
Neurology: Clinical Practice
Pediatrics
Multiple Sclerosis Journal
Multiple Sclerosis and Related Disorders
Journal of the Neurological Sciences
Clinical and Experimental Immunology
Acta Neurologica Scandinavica
Multiple Sclerosis International
Journal for Neuroimaging, others

Advisory Committees

National

2007 - 2016 Scientific Review Committee, Member, New York State Multiple Sclerosis Consortium

2016 - present Steering Committee, Discontinuation Of Disease Modifying Therapies in Multiple Sclerosis (DISCOMS Trial), funded by Patient Centered Outcomes Research Institute and National Multiple Sclerosis Society

International

2014 - present Scientific Leadership Group, MSBase, a global MS registry
2014 - present Group Leader for NMOBase, A Global Neuromyelitis Optica Registry (substudy of MSBase Registry)
2014 - present Group Leader for EXPAND (Natalizumab Extended Dosing Registry within the MSBase Registry)
2013 - present Guthy-Jackson International Clinical Consortium & Biorepository Committee, Voting member
2016 Grant reviewer for PCORI. Patient-Centered Outcomes Research Institute

Professional Societies

2004 - present Member, American Academy of Neurology
2007 - present Member, New York State Multiple Sclerosis Consortium

Consultantships

Served on advisory board of Biogen-Idec and Genentech

Awards and Honors

1996 M. Wheeler Wigner Memorial Scholarship, Physics Department, Rutgers University
1996 Elected to National Physics Honor Society
2006 recipient of Serono-Pfizer MS Clinical Fellowship Award, an unrestricted education grant distributed by Brigham and Women's Hospital, Harvard Medical School
2010 John G. Gianutsos Award for Research and Educational Contributions, Department of Rehabilitation Medicine, Rusk Institute, NYU Medical Center
2013 - 2014 Super Doctors® New York Rising Stars List
2010 - 2016 Patients' Choice Award, Vitals®
2010 - 2016 Compassionate Doctor Recognition, Vitals®
2017 NJ Top Doctor award (USA Top Docs®)
2017 Fellow, American Academy of Neurology

Patents

"Harnessing altered intestinal microbial compositions for diagnosis, prevention, and treatment of Multiple Sclerosis". Ventura, Blaser, Kister et al. (patent pending)

Invited Talks

2008 "Common Myths in Multiple Sclerosis". Grand Rounds, Rehabilitation Department, NYU School of Medicine, New York
2008 "Rehabilitation in Multiple Sclerosis". The 34th Annual Comprehensive Review of Physical Medicine and Rehabilitation, Department of Rehabilitation, NYU School of Medicine, New York.
2010 "Neuromyelitis Optica Spectrum". Emerging Trends in MS: Mechanisms and Treatment (CME Course), NYU School of Medicine, New York
2014 "Multiple Sclerosis Mimickers", NYU Clinical Neurology Update: Approaches for 2014 and Beyond (CME course), NYU School of Medicine, New York

- 2014 "Natural History of Multiple Sclerosis", Diagnosing and Treating Multiple Sclerosis, (CME course) Barnabas Health, Livingston, NJ
- 2015 "Common Radiology Interpretation Errors in the MS Patient Population", Eastern Neuroradiological Society 27th Annual Meeting, Newport, RI
- 2015 "Doctor, can I stop my MS medicine (and, by the way, do I have MS)?" NYU Clinical Neurology Update: Approaches for 2015 and Beyond (CME course), NYU School of Medicine, New York
- 2016 "MS Mimics". The Cutting Edges in Stroke & The Classics and the Mysteries in Neurology (CME course), NYU School of Medicine, New York
- 2018 "Updates on Neuromyelitis Optica Spectrum Disorder and anti-Myelin Oligodendrocyte Antibody Syndromes". Grand Rounds, Department of Neurology, NYU Lutheran